Bicara Therapeutics 11/12/2024 Earnings Report $12.08 -0.03 (-0.25%) As of 04:00 PM Eastern Earnings HistoryForecast Bicara Therapeutics EPS ResultsActual EPS-$1.60Consensus EPS -$0.46Beat/MissMissed by -$1.14One Year Ago EPSN/ABicara Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABicara Therapeutics Announcement DetailsQuarterDate11/12/2024TimeBefore Market OpensConference Call ResourcesBCAX Earnings History Bicara Therapeutics Earnings HeadlinesBicara Therapeutics Initiates Corporate Presentation on Promising Corporate StrategyJanuary 20 at 2:04 AM | americanbankingnews.comBicara Therapeutics Inc. (BCAX)January 17, 2025 | uk.finance.yahoo.comDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.January 21, 2025 | Brownstone Research (Ad)Bicara Therapeutics (NASDAQ:BCAX) Stock Quotes, Forecast and News SummaryJanuary 17, 2025 | benzinga.comHC Wainwright & Co. Initiates Coverage of Bicara Therapeutics (BCAX) with Buy RecommendationDecember 7, 2024 | msn.comPromising Potential of Bicara Therapeutics’ Ficerafusp Alfa: A Buy Rating Supported by Innovative Dual-Targeting and Positive Trial ResultsDecember 6, 2024 | markets.businessinsider.comSee More Bicara Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bicara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bicara Therapeutics and other key companies, straight to your email. Email Address About Bicara TherapeuticsBicara Therapeutics (NASDAQ:BCAX), a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.View Bicara Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Abbott Laboratories (1/22/2025)Amphenol (1/22/2025)GE Vernova (1/22/2025)ICICI Bank (1/22/2025)Johnson & Johnson (1/22/2025)Kinder Morgan (1/22/2025)Procter & Gamble (1/22/2025)Progressive (1/22/2025)Travelers Companies (1/22/2025)CSX (1/23/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
